Rifalazil (also known as KRM-1648 and AMI-1648)[2] is an antibiotic substance that kills bacterial cells by blocking off the β-subunit in RNA polymerase.

The most common are Chlamydia infection, Clostridioides difficile associated diarrhea (CDAD), and tuberculosis (TB).

In a study conducted in 2005, it was found that combining rifalazil with vancomycin increased bacterial killing by a factor of 3.

It is a very good treatment for tuberculosis because rifalazil achieves a very high concentration in the blood cells and the lungs.

A longer half-life allows for fewer treatments and dosages, which makes this an up-and-coming drug for tuberculosis, CDAD, and chlamydia.